Session: SAT 248-267-Osteoporosis II
Poster Board SAT-265
Method: A total of 214 patients were included after excluding postmenopausal women and thyroid function affecting drugs users. The baseline thyroid function and bone turnover markers were examined. Patients with Graves’ disease were followed up after treatment and compared with baseline state and controls for thyroid function and bone biomarkers in addition to RANK, OPG, M-CSF.
Results: Hyperthyroid patients had increased bone turnover markers. In the multivariate regression analysis, suppressed TSH was significantly associated with elevated osteocalcin (β = -0.54, P = 0.034) in addition to FT4 (β = 1.39, P <.001) and also associated with higher levels of ICTP (β = -0.28, P = 0.036) besides FT4 (β = 1.21, P <.001). In the treatment of patients with Graves’ disease, FT4 was decreased promptly followed by lowered 1CTP whereas TSH was increased in the late period followed by lowered osteocalcin. However, there were no difference in RANKL, OPG, and M-CSF between patients before and after treatment and controls.
Conclusion: Both TSH and thyroid hormone was significantly associated with bone metabolism. As shown in the temporal change after treatment of Graves’ disease, bone remodeling could be largely attributed to elevated FT4 by activating osteoclast and TSH seemed to have additional role by suppressing osteoblast. Future studies are needed to elucidate related molecular mechanism to enlarge our knowledge in bone metabolism and to find new treatment candidate for osteoporosis.
Nothing to Disclose: HJC, KWL, KHB
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters